The pharmaceutical industry is witnessing a strategic shift toward specialized autoimmune markets, with IgG4-related diseases representing a compelling investment opportunity within this evolving landscape. These rare but clinically significant disorders are attracting substantial attention from drug developers, investors, and healthcare systems worldwide, creating a...